Performance analysis of Acurx Pharmaceuticals (ACXP)
Annual Return
Over the past 3 years, ACXP has had an average annual return of -67.28%, underperforming the benchmark SPY, which returned +19.63% annual.
Over the past 5 years, ACXP has had an average annual return of -57.91%, underperforming the benchmark SPY, which returned +12.73% annual.
Since Jun 25, 2021, ACXP has had an average annual return of -59.97%, underperforming the benchmark SPY, which returned +13.21% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -39.24% | -84.69% | -78.74% | -3.77% | -7.91% | -45.23% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.06% | -36.67% | +147.37% | -41.70% | -8.76% | -21.60% | -2.04% | -39.24% | |||||
| 2025 | -10.27% | -2.92% | -45.05% | +10.32% | -9.54% | +31.24% | -36.17% | -29.06% | -7.17% | +16.91% | -22.64% | -35.77% | -84.69% |
| 2024 | -14.63% | -12.21% | -14.65% | -10.21% | +14.10% | -10.34% | -4.00% | +1.83% | -13.63% | -1.04% | -33.53% | -34.85% | -78.74% |
| 2023 | -9.54% | -8.06% | +4.53% | -13.57% | +3.67% | -14.51% | -23.40% | -4.94% | -22.28% | +256.71% | -34.21% | +8.81% | -3.77% |
| 2022 | -3.74% | -12.52% | -9.87% | +13.74% | -27.90% | +40.92% | -5.56% | -2.51% | -14.04% | +2.68% | +3.56% | +24.76% | -7.91% |
| 2021 | -19.14% | -10.97% | -8.97% | -0.58% | -2.73% | -3.99% | -9.98% | -45.23% |
Drawdown analysis of Acurx Pharmaceuticals (ACXP)
The maximum drawdown for the ACXP was -99.14%, occurring on Mar 6, 2026. This drawdown has not yet recovered.
The current ACXP drawdown is -99.04%.
Since Jun 25, 2021 ACXP has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.14% | Jun 25, 2021 | 1178 | Mar 6, 2026 | Ongoing | Ongoing | Ongoing |